← brief for 2026-11-03 · Slowing decline

Denosumab in multiple myeloma patients with severe renal impairment: a multicenter phase 2 study

Article No results yet Peer reviewed

Key takeaways

This is a phase 2 study of a bone drug called denosumab. It looked at patients with multiple myeloma and severe kidney problems. The abstract explains why this drug is used, but it does not give the final results. It is a study that is reporting on a specific group.

Who did this work

Elizabeth O’Donnell (Harvard University) · Omar Nadeem (Harvard University) · Jacob P. Laubach (Harvard University) · Giada Bianchi (Harvard University) · Andrew Robert Branagan (Harvard University) · Brea C. Lipe (University of Rochester Medicine) · Paul Gerard Guy Richardson (Harvard University) · Ehsan Malek (University Hospitals of Cleveland) · Robb S. Friedman (Newton Wellesley Hospital) · Ajay K. Nooka (Emory University) · Robert Allyn Redd (Dana-Farber Cancer Institute) · Noopur S Raje (Harvard University)

Source

Article · OpenAlex, Kidney disease concept sweep (verified C2778653478) · 2026-11-02
https://doi.org/10.1038/s41408-026-01656-y